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ABSTRACT
Background: Trauma patients are characterised by
alterations in the immune system, increased exposure to
infectious complications, sepsis and potentially organ
failure and death. Glutamine supplementation to
parenteral nutrition has been proven to be associated with
improved clinical outcomes. However, glutamine
supplementation in patients receiving enteral nutrition
and its best route are still controversial. Previous trials
have been limited by a smallsample size, use ofsurrogate
outcomes or a limited period of supplementation. The aim
of this trial is to investigate if intravenous glutamine
supplementation to trauma patients receiving enteral
nutrition is associated with improved clinical outcomes in
terms of decreased organ dysfunction, infectious
complications and other secondary outcomes.
Methods/design: Eighty-eight critically ill patients
with multiple trauma receiving enteral nutrition will be
recruited in this prospective, triple-blind, block-
randomised, placebo-controlled clinical trial to receive
either 0.5 g/kg/day intravenous undiluted alanyl-
glutamine or intravenous placebo by continuous
infusion (24 h/day). Both groups will be receiving the
same standard enteral nutrition protocol and the same
standard intensive care unit care. Supplementation will
continue until discharge from the intensive care unit,
death or a maximum duration of 3 weeks. The primary
outcome will be organ-dysfunction evaluation
assessed by the pattern of change in sequential organ
failure assessment score over a 10-day period. The
secondary outcomes are: the changes in total
sequential organ failure assessment score on the last
day of treatment, infectious complications during the
ICU stay, 60-day mortality, length of stay in the
intensive care unit and body-composition analysis.
Discussion: This study is the ﬁrst trial to investigate the
effect of intravenous alanyl-glutamine supplementation in
multiple trauma patients receiving enteral nutrition on
reducing severity of organ failure and infectious
complications and preservation of lean body mass.
Trial registration number: This trial is registered at
http://www.clinicaltrials.gov. NCT01240291.
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ARTICLE SUMMARY
Article focus
- Glutamine supplementation has demonstrated
improved clinical outcomes in patients receiving
parenteral nutrition. However, its effect and the
best route of administration remain inconclusive
for patients receiving enteral nutrition.
- Previous trials for patients receiving enteral
nutrition had a number of limitations.
Key messages
- This proposed research with other worldwide trials
will have implications in improving the practice of
glutamine supplementation in critically ill patients.
- The results of this trial will provide pilot data for
a large multicentre trial to investigate the effect of
intravenous glutamine supplementation in
multiple trauma patients receiving enteral nutri-
tion on infectious complications and mortality.
Strengths and limitations of this study
- This is the ﬁrst trial to investigate the effect of
intravenous glutamine supplementation in trauma
patients receiving enteral nutrition on organ failure,
infectious complications and body composition.
- Supplementation is continued as long as the
patient is in the intensive care unit or to
a maximum duration of 21 days.
- This is a single-centre trial, so it is not powered
to investigate the effect of intravenous alanyl-
glutamine supplementation on mortality.
- Data will not be applicable to trauma patients
with severe renal failure or hepatic impairment.
- The long-term outcomes (eg, 6-month mortality)
are not assessed.
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Open Access ProtocolBACKGROUND
Multiple trauma is life-threatening, not only from the
initial trauma insult alone, but also from the subsequent
massive immunological dysfunctions and metabolic alter-
ations.
1 Multiple trauma is characterised by impairment
in the immune response
23that is associated with an
increased rate of infectious complications and death.
45
In fact, infectious complications in critically ill
patients remain a serious problem worldwide and are
independently associated with higher hospital mortalities.
6
METABOLIC RESPONSE TO CRITICAL ILLNESS
Critical illness exhibits a metabolic response that is
characterised by hypermetabolism,
7 insulin resistance
associated with hyperglycaemia,
89lipolysis
10 and accel-
erated protein catabolism
7 that might reach up to 2%
per day.
11 In critically ill patients, net protein catabolism
is accelerated,
12e16 despite vigorous nutritional support
and increased protein intake.
13 14 Loss of lean body mass
during critical illness is considered a major clinical
problem that delays wound healing and recovery. In
parallel, there is a depletion of glutamine levels in
muscle.
11 16 Although glutamine production is increased
in critically ill patients, it is not sufﬁcient to maintain
intracellular levels of glutamine in muscle.
17
GLUTAMINE SUPPLEMENTATION
Glutamine, traditionally considered as a non-essential
amino acid under normal physiological conditions, has
received considerable attention in becoming ‘condi-
tionally indispensable’ during catabolic states such as
major surgery and critical illness.
18 Under stress and
catabolic conditions such as major surgery,
19 burn
injury
20 21 and multiple trauma,
22e25 there is a severe
depletion of glutamine levels in plasma. It has been
reported that a low plasma glutamine level at intensive-
care unit (ICU) admission is an independent risk factor
for mortality.
26
In the past two decades, numerous trials have docu-
mented beneﬁcial effects of glutamine supplementation
in critically ill patients.
23 27e35 There is good evidence
that glutamine supplementation in critically ill patients
receiving parenteral nutrition is associated with
improved clinical outcomes in terms of improved
survival rate, decreased infections, costs and reduced
hospital length of stay.
27e31 36 Indeed, currently gluta-
mine supplemented parenteral nutrition is the standard
of care in critical illness.
37e39 However, there are also
recent trials that failed to demonstrate any beneﬁcial
effect of supplemented total parenteral nutrition.
40 41 It
has been reported that intravenous glutamine supple-
mentation in surgical patients counteracts muscle
glutamine depletion and can enhance the rate of muscle
protein synthesis.
42 43 However, in critically ill patients,
although intravenous glutamine supplementation
increased plasma glutamine levels, muscle glutamine
concentration and muscle protein synthesis were only
marginally inﬂuenced.
44 45 This might be explained by
the increased demand on glutamine in critically ill
patients.
Glutamine supplementation in patients receiving
enteral nutrition and its best route are still debated.
Despite the numerous numbers of clinical trials that
have been conducted to investigate the beneﬁcial effects
of glutamine supplementation in patients receiving
enteral nutrition,
23 32e35 46e50 the results are conﬂicting
and inconclusive. Enteral nutrition is advocated in crit-
ically ill and trauma patients when the gastrointestinal
tract is functioning in terms of reduced infectious
complications.
51e53 Therefore, enteral glutamine
supplementation is attractive when tube feeding is
carried out.
54 However, in clinical practice with enteral
nutrition, especially in critically ill patients, there is
a clear difference between what is targeted and what
actually could be delivered.
46 It has been documented
that the systemic bioavailability of glutamine via the
enteral route is less than via the intravenous route.
55 To
overcome the problem of not reaching the target dose
by the enteral route, and the possibility of altered gut-
absorption capacity, a number of trials investigated the
effect of intravenous glutamine supplementation in
patients receiving enteral nutrition.
56e59 However, these
trials were: pilot studies, including both enteral- and
parenteral-nutrition-receiving patients, and most
measured surrogate outcomes.
As primary outcomes in nutritional intervention trials,
infectious complications and mortality require a large
number of participants.
60e62 Therefore, critical illness
scores that relate to mortality and infectious morbidity
end points have been considered as an alternative
outcome measure.
60 61 Multiple organ failure is consid-
ered as a reliable predictor of mortality in critically ill
patients.
63 Since mortality is not a feasible endpoint in
a single-centre trial, we decided to use sequential organ
failure assessment (SOFA) score as a surrogate primary
outcome measure.
The aim of this study is to determine whether
providing intravenous alanyl-glutamine (0.5 g/kg/day)
will be associated with improved clinical outcomes in
terms of reduced severity of organ dysfunction and
reduction in infectious morbidity in mechanically venti-
lated trauma patients receiving enteral nutrition. To our
knowledge, no study has investigated the effect of
intravenous alanyl-glutamine supplementation in
multiple trauma patients receiving enteral nutrition on
organ dysfunction and infectious morbidity. In addition,
our study is the ﬁrst clinical trial to investigate the effect
of intravenous alanyl-glutamine supplementation on
body composition in multiple trauma patients.
RESEARCH QUESTIONS
1. What is the effect of intravenous alanyl-glutamine
supplementation compared with placebo in multiple
trauma patients receiving enteral nutrition on organ
dysfunction; Sequential Organ Failure Assessment
(SOFA); (ΔSOFA)?
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GLINT Study2. What is the effect of intravenous alanyl-glutamine
supplementation compared with placebo in multiple
trauma patients receiving enteral nutrition on infec-
tious morbidity, 60-day mortality, length of stay in
ICU, length of stay in hospital, number of days on
mechanical ventilation, number of days of antibiotic
use during ICU stay, and fat-free mass and fat
percentage as a measure of body composition?
METHODS/DESIGN
The GLutamine supplementation IN Trauma patients
receiving enteral nutrition study protocol (GLINT)
Study is a prospective, interventional, single-centre,
concealed block-randomisation, triple-blinded (subject,
care givers, outcome assessor), placebo-controlled trial
(ﬁgure 1). The study has been designed with the
Consolidated Standards for Reporting of Trials guide-
lines.
64 The trial will be conducted in a tertiary univer-
sity-afﬁliated intensive-care unit at Royal Brisbane and
Women’s Hospital (RBWH), Brisbane, Australia. It has
been approved by the University of Queensland Human
Ethics Committee (Project No 2010001359) and the
Human Ethics Committee of RBWH (Protocol No
HREC/10/QRBW/131). Dipeptiven is unregistered in
Australia, so for the purpose of this trial, clinical trial
notiﬁcation (CTN) has been obtained from the Thera-
peutic Goods Administration of Australia (TGA) (trial
no 2010/0623). The patients will be enrolled in the
study after informed consent has been obtained from
next of kin.
The duration of supplementation in many previous
trials was short (eg, 3e7 days), which might explain why
no effect has been found in many of them. In addition, it
has been considered that a minimum of 5 days of
glutamine supplementation is necessary to show an
effect on infectious complications.
23 Therefore, we
decided to continue supplementation for a longer
period of time (ie, 3 weeks) as long as the patient
remained in the ICU. Also, the maximum approved dose
(0.5 g/kg/day alanyl-glutamine) to ensure maximal
beneﬁcial effect will be given.
SELECTION OF PARTICIPANTS
Inclusion criteria
The inclusion criteria are: age 18e85 years, patients
admitted with a diagnosis of multiple trauma requiring
mechanical ventilation, patients requiring enteral feeding
for >48 h, expected length of stay in the ICU >48 h,
functional access for enteral tube feeding and central
access for administration of test solution, and negative
b HCG (pregnancy test) in females (18e60 years).
Exclusion criteria
The exclusion criteria are: pregnancy, age <18 years,
signiﬁcant hepatic failure (patients with Childs C
Cirrhosis), severe renal failure (glomuerular ﬁltration
rate (eGFR) <50 ml/min), patients with inborn errors of
amino-acid metabolism (eg, phenylketonurea), patients
with metabolic acidosis (pH<7.35), not expected to be
in the ICU >48 h (owing to imminent death), unable to
tolerate enteral nutrition within 72 h, enrolment in
other ICU intervention study if contraindicated, patients
in whom parenteral nutrition is required from the outset
or an absolute contraindication to enteral nutrition.
Randomisation
Participants will be randomised by opaque sealed enve-
lope after enrolment. Numbers in the envelope have
been generated by a computer-generated randomisation
(http://www.randomization.com) table based on blocks
of four to assign patients to treatment group or placebo
group. The solutions will be prepared by the unblinded
pharmacist (JR) and placed into identical infusion bags.
The study solutions will be indistinguishable by colour,
smell or taste.
INTERVENTION
Intervention arm
This group (randomly allocated) will receive intravenous
alanyl-glutamine (0.5 g/kg body weight/day; 2.5 ml/kg
body weight; ie, 0.35 g L-glutamine/kg body weight/day;
Dipeptiven, Fresenius-Kabi, Bad Homburg, Germany) by
continuous infusion (24 h/day) through a dedicated
lumen via central venous access until discharge from the
ICU, death, or for a maximum duration of 3 weeks.
Dipeptiven is a solution (20%, w/v) of glutamine-
containing dipeptide, N(2)-L-alanyl-L-glutamine. The
normal body weight will be calculated according to
Broca’s formula (normal body weight (kg)¼patient
height (cm)e100). This formula has been used by the
‘Reducing Deaths Due to Oxidative Stress’ study,
65 and
we elected to use it, as each patient’s height can be
accurately measured. This group represents the treat-
ment group. It has been advised that for the intervention
nutrient to have beneﬁcial efﬁcacy, it should be admin-
istered as soon as possible after the injury.
66 Therefore,
the intervention solution will be initiated within 24e48 h
after admission to the ICU and independent from the
start of enteral nutrition (ie, supplementation will be
started even before enteral nutrition starts). Figure 1 Trial ﬂow chart. IV, intravenous.
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This group will receive intravenous placebo (normal
saline; 0.9% NaCl; 2.5 ml/kg/day) by continuous infu-
sion (24 h/day) through a dedicated lumen via central
venous access until discharge from the ICU, death or for
a maximum duration of 3 weeks.
All patients in both groups will receive standard,
polymeric, high-caloric, high-protien enteral formula
(1.2 kcal/1 ml; 12 g/l ﬁbre; 55.5 g/l protein) and start at
a rate of 40 ml/h according to the standard feeding
protocol followed at RBWH.
67 Enteral nutrition will be
targeted to be initiated within 24e48 h, and the aim is to
reach the target goal by day 3. If enteral nutrition has
failed by day 3 post-ICU admission, parenteral nutrition
will be started. It will not be initiated until all efforts to
maximise enteral nutrition have been attempted,
including motility agents and small-bowel feeding. If the
subject continues to require enteral nutrition after
3 weeks or is discharged from the ICU, intravenous
supplementation will be discontinued.
ENDPOINTS
Primary endpoints
Outcome measures will be taken by a blinded investi-
gator. The primary outcome measure will be taken daily
until discharge from the ICU, death or maximum
duration of 10 days.
The primary endpoint is organ dysfunction evaluation
assessed by the pattern of change in SOFA score over
a period of 10 days. This will be analysed by comparing
daily measured SOFA score subtracted from the baseline
SOFA score (the delta daily total SOFA score) each day
and calculating the regression coefﬁcients for each
resulting slope. The regression coefﬁcients for the two
groups will be compared with a Student t test as
described by Beal et al.
60
Secondary endpoints
The secondary outcomes are:
1. The change in total SOFA score on the last day
of treatment, where the change in total SOFA
score¼baseline total SOFA scoreelast day of treat-
ment total SOFA score. A higher number indicates an
improvement compared with baseline.
2. Infectious morbidity (ventilator-associated pneu-
monia, urinary-tract infection, bloodstream infection,
sinusitis, abdominal infection, sepsis) during the ICU
stay or a maximum duration of 3 weeks. We will use
standardised deﬁnitions to limit bias, so modiﬁed
criteria of the Centre for Disease Control deﬁnitions
will be followed.
68
3. Sixty-day mortality.
4. Length of stay in the ICU.
5. Length of stay in hospital (if delayed discharge owing
to placement problems, will record from the date the
patient is regarded as ﬁt for discharge by medical staff).
6. Number of ventilator-free days (VFD). A ventilator-free
day is deﬁned as a 24 h period from midnight to
midnight that a patient is breathing independently of
theventilator.However,adaywithtracheotomycannula
in place but without mechanical ventilation before
extubation will be counted as a ventilator-free day.
7. Number of days of antibiotic use during the ICU stay.
8. Fat-free mass and fat percentage as a measure of body
composition (bioelectric impedance spectroscopy
(BIS)).
69 BIS will be measured using a multifrequency,
spectroscopy bioelectrical impedance analyser
(ImpediMed SFB7, ImpediMed, Brisbane, Australia).
This will be measured at baseline, and once weekly
during the ICU stay or a maximum of 3 weeks. BIS
relies on passing a small electric current through the
body and measuring impedance (resistance) to the
current. This is dependent on total body water and, in
combination with information on weight, height and
gender, allows an estimation of fat percentage and fat-
free mass. In general, bioelectrical impedance anal-
ysis has been validated to be used as a tool for
nutritional status assessment in critically ill patients,
70
patients with chronic obstructive pulmonary disease
and patients with acute respiratory failure,
71 and can
give a reasonable estimation of the change in body
composition during an ICU day.
Routine ICU blood tests will be recorded daily until
discharge from the ICU or a maximum duration of
3 weeks, including white-blood-cell count, platelets,
nuetrophils, lymphocytes, monocytes, urea, creatinine,
protein and albumin. In 15 patients, C-reactive protein
will be measured as a marker of inﬂammation and
plasma amino acids proﬁle will be measured and at
baseline, day 7, day 14 and day 21.
STATISTICS
Sample-size calculation
Statistical analysis for the primary point (the delta daily
total SOFA score plotted each day over 10 days) would
involve linear regression power analysis where y¼delta
daily total SOFA score and x¼day of measurement.
Linear regression would therefore provide the slope of
line, which is similar to the methodology used by Beale
et al.
60 Using assumptions about the primary endpoint,
the analysis indicated that a sample size of 41 in each
group is required to differentiate between the two
groups with slopes similar to that reported by Beale
et al,
60 that is a change in slope from ( 0.15) under the
null hypothesis to ( 0.30) under the alternative
hypothesis when the SD of the mean is 3.00, the SD of
the residuals is 1.00, and the two-sided signiﬁcance level
is 0.05. Allowing for dropouts, 88 patients will be
recruited.
Statistical analysis
Statistical analysis will be performed using PASW soft-
ware version 19.0 (SPSS). A baseline comparison of
demographics, severity of illness and baseline measures
will be carried out between each group, using a combi-
nation of Student t tests and c
2 tests. Dichotomous data
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mortality) will be compared between groups using the
c
2 test. Normally distributed continuous data will be
analysed by a parametric test (ie, Student t test or
ANOVA) and reported as mean6SD. Non-normally
distributed continuous data will be analysed with an
appropriate non-parametric test (eg, ManneWhitney U
test) and reported as median6IQR. Data will be
analysed on the basis of intention-to-treat analysis (as
per randomisation) and per protocol analysis for
patients who receive at least 5 days’ supplementation.
The differences will be considered statistically signiﬁ-
cant at p<0.05. An intention-to-treat analysis using
a carry-forward analysis for missing data will be
performed for all participants including withdrawn
patients.
MONITORING
Regular team meetings will be held. The principal
investigator, coinvestigators and other researchers will
review study progress at these meetings, address perti-
nent issues and identify further actions to be taken. The
principal investigator will ensure via this regular review
process that data are managed appropriately (ie, stored
in ‘potentially reidentiﬁable’ fashion) and that appro-
priate steps are taken with regard to data cleansing and
dissemination of results. Also, an independent Data
Monitoring Committee will monitor patients’ safety
and treatment efﬁcacy data while the trial is ongoing.
This committee is independent of the sponsor and
investigators, and has no competing interests.
CONFIDENTIALITY AND PRIVACY
Participants will not be identiﬁed by name, and conﬁ-
dentiality of the information in the medical report will
be preserved. The information on subjects will be stored
in both paper copies, on computer and on a CD in
a coded manner. The data will be stored in a locked
ﬁling cabinet in a locked ofﬁce. The computer will be
password-protected. The data will be stored for 15 years
and disposed after this period in a conﬁdential
shredder.
STUDY TERMINATION
There is no plan for early trial termination. The study
will be considered terminated upon completion of all
patient treatments and evaluations. If an interim analysis
is carried out, Bonferroni corrections will be applied in
the ﬁnal stage (ie, signiﬁcance p<0.05 will be changed to
p<0.025, which will require a doubling of the number of
subjects). However, there is no plan to carry out any
interim analyses.
ADVERSE EVENTS REPORTING
All serious adverse events (SAEs) that are thought to be
related to treatment are subject to expedited reporting
and will be reported within 24 h. The principal investi-
gator will be responsible for follow-up of all SAEs to
ensure all details are available. The principal investigator
will be responsible for reporting to the regulatory
authorities (Therapeutic Goods Administration in
Australia), the study supplement manufacturer (Frese-
nius Kabi), the Royal Brisbane and Women’s Hospital
Research Ethics Committee, and University of Queens-
land ethics committee all SAE events that occur in the
study.
DISCUSSION
This proposed trial with other worldwide trials will have
implications in improving the practice of glutamine
supplementation in critically ill patients. However, the
results of this trial will only be relevant to trauma
patients receiving enteral nutrition. It may not be
directly applicable to other critically ill patients. The
data for this study will not be applicable to trauma
patients with severe renal failure or hepatic impairment.
This trial is a single-centre trial, so it is not powered to
investigate the effect of intravenous alanyl-glutamine
supplementation on mortality. This study will not be
assessing underlying immunological or inﬂammatory
changes, so the exact mechanism of any beneﬁcial
effects will not be clearly understood. Long-term
outcomes are not assessed in this trial.
However, this trial is the ﬁrst to investigate the effect of
intravenous alanyl-glutamine supplementation in
multiple trauma patients receiving enteral nutrition on
organ dysfunction, infectious complications and body
composition. We anticipate that the data from this
study will add to the current practices of intravenous
glutamine supplementation in trauma patients.
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